The directed share issue (which was completed on December 6, 2019) of approximately 3,7 million shares will raise proceeds of approximately 300 MSEK.
The board of directors of Camurus has, based on the authorization granted by the annual general meeting on 9 May 2019, resolved on a directed share issue of 3,660,000 new shares at a subscription price of SEK 82 per share (the “Issue”), which means that the Company receives approx. 300 MSEK before transaction costs. The subscription price in the Issue has been determined through an accelerated bookbuilding procedure.
The purpose of the Issue is to finance the Phase III program for CAM2029 in neuroendocrine tumors, preapproval and premarketing activities for CAM2038 in chronic pain in EU and Australia, and general corporate development. The reason for the deviation from the shareholders’ preferential rights is to raise capital in a time and cost-effective manner.